A Phase 1 Study of UB-VV111 With and Without Rapamycin in Relapsed/Refractory CD19+ B-cell Malignancies
מצבים רפואיים
Lymphoma, B-Cell · Lymphoma, Non-Hodgkin (NHL) · Lymphoma, Large B-Cell, Diffuse (DLBCL) · Chronic Lymphocytic Leukemia (CLL)
סיכום בשפה פשוטהבעזרת בינה מלאכותית
הסיכום נכתב על־ידי מודל שפה והוא ניסיוני. המידע עלול להיות חלקי או שגוי ואינו תחליף לייעוץ רפואי.
מיקומים
City of Hope, Duarte, California, United States
Contact: Principal Investigator (Tanya Siddiqi, MD)The David and Etta Jonas Center for Cellular Therapy, Chicago, Illinois, United States
Contact: Study coordinator (Michael Bishop, MD) · cancerclinicaltrials@bsd.uchicago.edu · 773-702-6149Contact: Principal Investigator (Michael Bishop, MD)Washington University School of Medicine/Siteman Cancer Center, St Louis, Missouri, United States
Contact: Principal Investigator (Zachary Crees, MD)University of Nebraska Medical Center, Omaha, Nebraska, United States
Contact: Principal Investigator (Matthew Lunning, D.O. F.A.C.P.)University of Cincinnatti Medical Center, Cincinnati, Ohio, United States
Contact: Principal Investigator (Zulfa Omer, MD)Fred Hutch Cancer Center, Seattle, Washington, United States
Contact: Principal Investigator (Ajay Gopal, MD/FACP)Royal North Shore Hospital, Saint Leonards, New South Wales, Australia
Contact: Principal Investigator (Cameron Turtle, MBBS, PhD)St. Vincent's Hospital Melbourne, Fitzroy, Victoria, Australia
Contact: Principal Investigator (Matthew Ku, MD)
מובילי המחקר
Jacob Garcia, MD
Study Director
Umoja Biopharma